Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer
JNCI Cancer Spectrum · 2024
DOI: 10.1093/jncics/pkad107 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Marina Elena Cazzaniga und 24 weiteren Autor:innen. Beteiligte Einrichtung: Phase 1 Research Unit, IRCCS San Gerardo dei Tintori, Monza, MB, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rna Diagnostics, Inc.
Themen: Onkologische Pflege
Abstract (Originalsprache)
In previously reported retrospective studies, high tumor RNA disruption during neoadjuvant chemotherapy predicted for post-treatment pathologic complete response (pCR) and improved disease-free survival at definitive surgery for primary early breast cancer. The BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) prospective clinical trial (NCT03524430) seeks to validate these prior findings. Here we report training set (Phase I) findings, including determination of RNA disruption index (RDI) cut points for outcome prediction in the subsequent validation set (Phase II; 454 patients). In 80 patients of the training set, maximum tumor RDI values for biopsies obtained during neoadjuvant chemotherapy were significantly higher in pCR responders than in patients without pCR post-treatment (P = .008). Moreover, maximum tumor RDI values ≤3.7 during treatment predicted for a lack of pCR at surgery (negative predictive value = 93.3%). These findings support the prospect that on-treatment tumor RNA disruption assessments may effectively predict post-surgery outcome, possibly permitting treatment optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Phase 1 Research Unit, IRCCS San Gerardo dei Tintori, Monza, MB, Italy.
- School of Medicine and Surgery, Milano Bicocca University, Monza, MB, Italy.
- Division of Medical Oncology, Washington University, Saint Louis, MO, USA.
- Institut Cancérologie Strasbourg Europe, Strasbourg, France.
- Department of Gynecology and Obstetrics, Universitätsklinikum Münster, Münster, Germany.
- Breast Cancer Unit, ASST of Cremona and Department of Life Sciences, University of Trieste, Trieste, Italy.
ORCID-Profile: Eva M Ciruelos, Lacey Pitre, Amadeo Parissenti, Maureen E Trudeau
Förderung
- Rna Diagnostics, Inc
Zitieren
APA
Cazzaniga, M. E., Ademuyiwa, F., Petit, T., Tio, J., Generali, D., Ciruelos, E. M., Califaretti, N., Poirier, B., Ardizzoia, A., Hoenig, A., Lex, B., Mouret-Reynier, M. A., Giesecke, D., Isambert, N., Masetti, R., Pitre, L., Wrobel, D., Augereau, P., Milani, M., …, & Trudeau, M. E. (2024). Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkad107
Vancouver
Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, et al. Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkad107
BibTeX
@article{Cazzaniga2024,
author = {Cazzaniga, Marina Elena and Ademuyiwa, Foluso and Petit, Thierry and Tio, Joke and Generali, Daniele and Ciruelos, Eva M and Califaretti, Nadia and Poirier, Brigitte and Ardizzoia, Antonio and Hoenig, Arnd and Lex, Benno and Mouret-Reynier, Marie-Ange and Giesecke, Dagmar and Isambert, Nicolas and Masetti, Ricardo and Pitre, Lacey and Wrobel, Denise and Augereau, Paule and Milani, Manuela and Rask, Sara and Solbach, Christine and Pritzker, Laura and Noubir, Sanaa and Parissenti, Amadeo and Trudeau, Maureen E},
title = {Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer},
journal = {JNCI Cancer Spectrum},
year = {2024},
doi = {10.1093/jncics/pkad107}
}
EUVIMED